Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

An evaluation of liraglutide including its efficacy and safety for the treatment of obesity

Lin, Chen-Hsiu, Shao, Li, Zhang, Yu-Mei, Tu, Yu-Ju, Zhang, Yuzhen, Tomlinson, Brian, Chan, Paul, Liu, Zhongmin · 2020 · Expert Opinion on Pharmacotherapy

Abstract

Introduction: The prevalence of obesity is increasing worldwide and associated conditions, particularly type 2 diabetes mellitus (T2DM), also show increasing prevalence. Lifestyle intervention should be the first line of management for obesity but additional pharmacotherapy is often required and bariatric surgery is appropriate in more severe cases. Drugs acting as glucagon-like peptide-1 receptor agonists (GLP-1RAs) developed for the management of T2DM reduce body weight and liraglutide is the first GLP-1RA to be approved for the treatment of obesity in patients with and without T2DM.Areas covered: In this review of relevant published material, the authors summarize the pharmacokinetics, pharmacodynamics, clinical efficacy and safety of liraglutide for the treatment of obesity.Expert opinion: Liraglutide effectively reduces body weight and body fat through mechanisms involving reduced appetite and lowered energy intake, independent of its glucose-lowering effects. Like most of the other medications currently available for obesity, liraglutide has some common adverse effects, although generally not serious ones. Liraglutide has additional benefits in reducing cardiovascular events in patients with T2DM but the cost and the need for daily injections may limit its use in obesity. Newer GLP-1RAs, such as semaglutide, or other drugs in development for obesity may have advantages over liraglutide.

Overview

Integrity signals

Registry

Crossref · 10.1080/14656566.2019.1695779

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 78 · Cited by 65

Metadata

Authors
Lin, C.-H., Shao, L., Zhang, Y.-M., Tu, Y.-J., Zhang, Y., Tomlinson, B., Chan, P., & Liu, Z.
Affiliations
  • Taipei Medical University (TW)
  • Tongji University (CN)
  • Macau University of Science and Technology (MO)
  • Wan Fang Hospital (TW)
Corresponding author
  • Chan, Paul
  • Liu, Zhongmin
Venue
Expert Opinion on Pharmacotherapy
Published
2019-12-02
Volume
21
Issue
3
Pages
275-285
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W2992083029
Cited by
65
References
78
Citations by year
2026: 4 · 2025: 7 · 2024: 18 · 2023: 14 · 2022: 13 · 2021: 5 · 2020: 4
FWCI
3.41
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
liraglutide, obesity, GLP-1 receptor agonists, type 2 diabetes, weight loss, pharmacokinetics, pharmacodynamics, adverse effects, cardiovascular events, semaglutide, appetite suppression
MeSH terms
Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Body Weight, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. https://app.cochat.ai/papers/10.1080/14656566.2019.1695779
The paper
Lin, C.-H., Shao, L., Zhang, Y.-M., Tu, Y.-J., Zhang, Y., Tomlinson, B., Chan, P., & Liu, Z. (2020). An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2019.1695779

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.